Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, Alpha Diallo, Joe Eustace et al.|Critical Care|2023Cited by 47
Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trialHans‐Kittil Viermyr, Marius Trøseid, Kristian Tonby et al.|EBioMedicine|2024Cited by 7
Efficacy and Safety of Baricitinib for the Treatment of Hospitalized Adults with Severe or Critical COVID-19 (Bari-SolidAct): A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 TrialMarius Trøseid, Alpha Diallo, Fridtjof Lund‐Johansen et al.|SSRN Electronic Journal|2022Cited by 1
Safety of Baricitinib in Vaccinated Patients with Severe and Critical COVID-19. Sub Study of the Randomised Bari-SolidAct TrialHans‐Kittil Viermyr, Marius Trøseid, Kristian Tonby et al.|SSRN Electronic Journal|2024Cited by 1